Michael Cherny
Stock Analyst at Leerink Partners
(4.39)
# 355
Out of 5,124 analysts
110
Total ratings
61.9%
Success rate
15.04%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $173.53 | +21.02% | 3 | Oct 21, 2025 | |
| MCK McKesson | Maintains: Outperform | $785 → $850 | $820.29 | +3.62% | 15 | Sep 24, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $205.50 | -9.49% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $25.68 | +9.03% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.20 | +150.00% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $21.71 | +5.94% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $561.65 | -41.24% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $32.47 | +23.19% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $79.36 | -5.49% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $44.28 | +103.25% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $156.15 | +79.31% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $75.58 | +11.14% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $225.41 | +10.02% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $182.22 | +39.94% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.43 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $337.75 | -18.58% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $250.88 | +3.64% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.71 | +195.20% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $8.81 | +115.66% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.00 | +142.86% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $2.15 | +2,341.86% | 2 | Jan 5, 2022 |
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $173.53
Upside: +21.02%
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $820.29
Upside: +3.62%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $205.50
Upside: -9.49%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $25.68
Upside: +9.03%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.20
Upside: +150.00%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $21.71
Upside: +5.94%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $561.65
Upside: -41.24%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $32.47
Upside: +23.19%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $79.36
Upside: -5.49%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $44.28
Upside: +103.25%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $156.15
Upside: +79.31%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $75.58
Upside: +11.14%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $225.41
Upside: +10.02%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $182.22
Upside: +39.94%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $11.43
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $337.75
Upside: -18.58%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $250.88
Upside: +3.64%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.71
Upside: +195.20%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $8.81
Upside: +115.66%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.00
Upside: +142.86%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $2.15
Upside: +2,341.86%